Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Neurology·MeSH: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

Prevalence

5.0 / 100K

9 drugs in development·3 companies·5 clinical trials

Drug Pipeline by Phase

Phase 2(1)
DrugCompany
TAK-411Merus N.V. (MRUS)

Compare drugs

hyqvia vs tak-411hyqvia vs tak-771hyqvia vs tak-881

Frequently asked questions

How many drugs are in development for Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)?

BioSniper tracks 9 drugs in development for Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) across 3 companies.

How many clinical trials target Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)?

There are 5 clinical trials targeting Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) tracked by BioSniper.

What is the prevalence of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)?

The estimated prevalence of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) is approximately 5.0 per 100,000 population.

Deep-dive into Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis
    Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) — Drugs in Development & Clinical Trials | BioSniper